Navigation Links
New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Date:8/3/2008

Now is the time to anticipate and plan for various study outcomes

MEXICO CITY, Aug. 3 /PRNewswire/ -- The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report, Anticipating the Results of PrEP Trials, calling for increased action from governments, global health institutions, donors, researchers, and advocates to prepare for initial results - expected as early as 2009 - from the first trials of antiretroviral drugs being tested for HIV prevention, known as PrEP or pre-exposure prophylaxis. The report also provides the most up-to-date information about ongoing and planned PrEP research, and lays out an agenda for action on key issues that must be addressed as research on this promising HIV prevention intervention moves forward.

The new report is available online at http://www.avac.org/prep08.pdf.

PrEP clinical trials are currently planned or underway in countries in Africa, Asia, Latin America and North America. These studies are looking at the safety and efficacy of PrEP, an unproven strategy in which HIV negative people could take an antiretroviral drug (ARV), or combination of ARVs, on a regular basis in the hopes of reducing their risk of acquiring HIV.

The AVAC report was released today at a special session of researchers, advocates and other stakeholders, held at the XVII International Conference on AIDS in Mexico City to discuss the challenges of translating PrEP and other HIV prevention research into effective policy and practice.

"PrEP trials are taking place within a changing landscape of HIV prevention research," said AVAC Executive Director Mitchell Warren. "Disappointing results have emerged from recent studies of vaccine and microbicide candidates, while male circumcision was found to be partially effective at preventing HIV transmission in some populations and is being rolled out in some African countries.

"Although still unproven h
'/>"/>

SOURCE AIDS Vaccine Advocacy Coalition
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
2. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
3. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
4. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
5. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
6. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
7. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of proprietary compounded drug therapies, today ... financial results on Wednesday, May 13, 2015.  The company ... (1:30 p.m. PDT) on the same day to discuss ... The conference call and webcast will be open to ...
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... CHAPEL HILL, N.C. , May 1, 2015 /PRNewswire/ ... from payers for its high price but manufacturer Gilead ... programs, strategic worldwide pricing, and effective public relations campaigns. ... and promise of less severe side effects propelled the ... quarter of 2014, the therapy,s first quarter on the ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 3EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2
... Inc. (Nasdaq: STXS ) announced today financial results ... line with the preliminary results reported on October 13, 2010. ... margins, and reductions in both operating loss and net loss. ... million, compared to $13.3 million in the third quarter 2009. ...
... 2010 Cambrex Corporation (NYSE: CBM ) ... released on Wednesday, November 3, 2010 after the market ... conference call to discuss the third quarter 2010 financial ... November 4, 2010 at 8:30 a.m. Eastern Time Dial-in: ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become parents, Astroglide ... TTC™ (Trying to Conceive) . Unlike traditional lubricants that ... TTC™ is specially formulated to provide a better environment ... Disease Control, an average of one in eight ... pregnancy, and over 7.4 million women have ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 03, 2015 AvePoint, ... platforms and devices, today announced it is a ... Professionals (IAPP) Asia Privacy Forum, taking place May ... the event, AvePoint will showcase its compliance, risk, ... platforms. , Visit AvePoint for New Solutions ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... hernias are one of the most common conditions treated ... annually. Although ventral hernia repair (VHR) is a common ... infection has been identified as a consistent risk factor ... which appears in the November issue of The ...
... such as Viagra use is linked to development of vision ... disorders have used Viagra medicines. It is found that it ... cause risk of blindness. Men most at risk for the ... heart disease, high blood pressure and high cholesterol, among other ...
... Findings presented at the American Society of Therapeutic Radiation ... antigen (PSA) // significantly reduces the mortality associated with ... most prevalent type of cancer found in men after ... in the male reproductive system, which produces some of ...
... is essential for the lipid and carbohydrate metabolism, and ... to insulin.// The use of glucose by the peripheral ... has potential impact on long-term complications. ,In ... and an association between the proper metabolic control and ...
... and colleagues have identified a candidate gene, Sipa1, ... in cancer. Cancer mortality is most often the ... studies from Kent Hunter’s group demonstrated that the ... efficiency. They expressed the polyoma middle-T transgene in ...
... in women after menopause has been found to enhance ... cholesterol (the “good” cholesterol) in women, according to a ... and is characterized by decreased levels of the female ... the vagina and uterus. In addition the hormone ...
Cached Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Impotence drug such as Viagra may cause Vision Loss 2Health News:Carnitine deficiency in children and adolescents with type 1 diabetes 2Health News:Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis 2Health News:Testosterone Therapy can improve sexual function in postmenopausal women 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: